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Abstract
Background: Birth weight (BW) is often used as a proxy for 
gestational age (GA) in studies on preterm birth. Recent find-
ings indicate that, in addition to perinatal outcomes, sub-
jects born very preterm (VP; GA < 32 weeks) differ from those 
with a very low birth weight (VLBW; BW < 1,500 g) in postna-
tal growth up to their final height. Objective: To study 
whether neurodevelopmental and functional outcomes at 
the age of 19 years differ in VP and/or VLBW subjects. Meth-
ods: 705 19-year-old subjects from the Project on Preterm 
and Small-for-Gestational-Age Infants (POPS) cohort were 
classified as (1) VP+/VLBW+ (n = 354), (2) VP+/VLBW– (n = 
144), or (3) VP–/VLBW+ (n = 207), and compared with regard 
to IQ as assessed with the Multicultural Capacity Test-inter-
mediate level; neuromotor function using Touwen’s exami-
nation of mild neurologic dysfunction; hearing loss; self- and 
parent-reported behavioral and emotional functioning; ed-
ucational achievement and occupation; and self-assessed 
health using the Health Utilities Index and the London Hand-
icap Scale. Results: VP+/VLBW– infants, on average, had 
3.8-point higher IQ scores (95% confidence interval [CI] 0.5–
7.1), a trend towards higher educational achievement, 3.3-
dB better hearing (95% CI 1.2–5.4), and less anxious behav-
ior, attention problems, and internalizing behavior than to 
VP+/VLBW+ subjects. VP–/VLBW+ infants reported 1.8 in-
creased odds (95% CI 1.2–2.6) of poor health compared to 
VP+/VLBW+ subjects. Conclusions: At the age of 19 years, 
subjects born VP+/VLBW+, VP+/VLBW–, and VP-/VLBW+ 
have different neurodevelopmental and functional out-
comes, although effect sizes are small. Hence, the terms VP 
and VLBW are not interchangeable. We recommend, at least 
for industrialized countries, to base inclusion in future stud-
ies on preterm populations on GA instead of on BW.
© 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
Being born very preterm (VP; i.e., a gestational age 
[GA] of < 32 weeks) and/or with a very low birth weight 
(VLBW; i.e., a birth weight [BW] < 1,500 g) requires ad-
mission to a neonatal intensive care unit (NICU). Both 
entities have previously been associated with neurodevel-
opmental and functional problems in adolescence [1–9]. 
Despite their close resemblance, in contrast to VP birth, 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
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VLBW can be attributed to prematurity, intrauterine 
growth restriction (IUGR), or both.
Results of studies in infants with VLBW are often ex-
trapolated to preterm populations, and vice versa. How-
ever, previous research has shown that short-term out-
comes are significantly different between children born 
VP and/or with VLBW, with more neonatal morbidities 
in VP infants, and more small-for-GA (SGA) births 
among those with VLBW [10]. Moreover, long-term out-
comes also appear to differ, as we recently found that VP 
and VLBW subjects have significantly different growth 
patterns and final height [11]. Subjects born VP without 
VLBW attained a height close to the population reference 
mean, whereas those with VLBW remained approximate-
ly 1 SD shorter despite initial catch-up growth. Whether 
such differences between VP and VLBW subjects also 
translate into different long-term neurodevelopmental 
and functional outcomes is unknown.
In the past three decades, NICU care has improved 
dramatically and survival rates of infants born VP and/or 
with VLBW have increased substantially [12]. Among the 
improvements are the widespread application of antena-
tal glucocorticoid therapy, the introduction of synthetic 
surfactant, and a tendency towards more aggressive feed-
ing strategies, although regional differences in the treat-
ment of VP and VLBW infants do exist [13]. Therefore, 
the entities VP and VLBW can only be compared between 
populations that have received the same care.
We aimed to compare neurodevelopmental and func-
tional outcomes in adolescence between subjects born VP 
and/or with VLBW, using the data from the Project on 
Preterm and Small-for-Gestational-Age Infants (POPS) 
cohort. This cohort project is, to our knowledge, the only 
one which studied subjects born both VP and/or with 
VLBW into adolescence. 
Methods
Population
The POPS cohort included 94% (n = 1,338) of the infants born 
alive in 1983 in The Netherlands who were VP and/or had a VLBW. 
We could therefore distinguish between: (1) VP+/VLBW+, (2) 
VP+/VLBW–, and (3) VP–/VLBW+ infants. Subjects were fol-
lowed up throughout childhood until the age of 19 years, when the 
data for this study were collected.
Neurodevelopmental Outcomes
Cognitive Functioning
Cognitive functioning was quantified with the IQ measured 
with the Multicultural Capacity Test (MCT)-intermediate level 
[14]. The MCT has been validated for individuals aged ≥16 years 
from different ethnic backgrounds with an education ranging 
from five years of secondary school to university level. It assesses 
verbal and numerical intelligence, spatial visualization, speech flu-
ency, memory, reasoning, and speed of perception. Four subscales 
(linguistic capacity, mathematical capacity, logical reasoning, and 
spatial visualization) and a total score can be derived. Normative 
scores were expressed on a scale with a mean of 100 and a standard 
deviation of 15, based on the Dutch norm population. 
Neuromotor Function
Neuromotor function was assessed with the revised version of 
Touwen’s examination of minor neurologic dysfunction [15, 16]. 
It examines 5 subcategories (hand function, quality of walking, 
coordination, posture, and passive muscle tone), and comprises 34 
items, which are scored on a 3-point scale where 2 = “optimal per-
formance,” 1 = “slightly reduced performance,” and 0 = “poor per-
formance.” Total scores range between 0 and 68. 
Hearing
Hearing was assessed with pure-tone audiometry with a hand-
held audiometer for each ear separately. Auditory sensitivity was 
determined as the mean of the threshold levels at 500, 1,000, 2,000, 
and 4,000 Hz. Hearing loss in the best and worst ear was recorded.
Behavioral and Emotional Functioning
Behavior was studied with the self-reported Young Adult Self 
Report (YASR), and the parent/caretaker-reported Young Adult 
Behavior Checklist (YABCL). Both questionnaires were developed 
by Achenbach [17], and provide standardized scores on behavior, 
feelings, thoughts, and competences in people aged 18–30 years. 
The YASR contains 130 items, and the YABCL contains 109 items. 
Informants are required to rate items pertaining to the past six 
months, scored as 0 = “not true,” 1 = “sometimes true,” and 2 = 
“very often or often true.” Eight syndrome scales can be derived: 
Anxious/depressed, Withdrawn, Somatic complaints, Thought 
problems, Attention problems, Intrusive behavior, Aggressive be-
havior, and Delinquent behavior. In addition, 3 problem scales can 
be calculated: “Internalizing behavior” is the sum of the syndrome 
scales Anxious/depressed and Withdrawn; Aggressive behavior, 
Delinquent behavior, and Intrusive behavior comprise the prob-
lem scale “Externalizing behavior”; and the “Total problems scale” 
is the sum of all individual items.
Functional Outcomes
Educational Achievement
A self-report was used to assess past and current education. 
Responses were coded according to the highest level of education 
achieved or currently enrolled, using a revised version of The 
Netherlands Central Bureau of Statistics (CBS) classification [18]: 
no/primary education or special education (level 0); preparatory 
vocational education (level 1); intermediate vocational education 
or higher general secondary education (level 2); and higher voca-
tional education, preuniversity secondary education, or university 
(level 3). For some participants, responses allowed multiple cod-
ings for current education. In such cases, best- and worst-case cod-
ing was used, coded by two assessors. Consensus about discrepan-
cies was reached through discussion. Both worst- and best-case 
classifications were analyzed.
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Occupation
Participants also provided details on their current occupation 
through self-report. Participation was coded as follows: no job or 
education (severe problem); part-time job < 16 h/week with no edu-
cation, or part-time education without a job (moderate problem); 
part-time job 16–32 h/week, or part-time education with a job < 16 h/ 
week (mild problem); and full-time education, full-time job > 32 h/
week, or part-time education with a job 16–31 h/week (no problem).
Seventeen subjects did not correctly fill in the questionnaire, 
and their data were therefore excluded.
Health Status
The Health Utilities Index Mark 3 (HUI3) was used to deter-
mine health status and health-related quality of life. The HUI3 
consists of 8 attributes, focusing on functional capacity: vision, 
hearing, speech, ambulation, dexterity, emotion, cognition, and 
pain. All attributes have 5 or 6 levels [19], which were dichoto-
mized as “no problem” (levels 1 + 2) and “moderate to severe prob-
lem” (level ≥3) [4]. Subsequently, dichotomized attributes were 
combined as: 0 attributes affected (no problem), 1–2 attributes af-
fected (mild problem), 3–4 attributes affected (moderate prob-
lem), or ≥5 attributes affected (severe problem).
Perceived Health
The London Handicap Scale (LHS) was used to measure per-
ceived health. It measures disadvantages for six dimensions on a 
6-point hierarchical scale: mobility, physical independence (self-
care), occupation (daily activities), social integration, orientation, 
and economic self-sufficiency [20]. Coding of responses on the 
LHS was identical to the method used for the HUI3.
Statistics
Differences in functional outcomes, activities, and participa-
tion across the three groups were analyzed by multivariate linear 
or ordinal regression, depending on the measurement level of the 
outcome variable. Results were expressed as β (95% confidence 
interval [CI]) for linear regression, or odds ratio (OR) (95% CI) for 
ordinal regression. Next, analyses were adjusted for: (1) gender, 
socioeconomic status, and ethnicity (Model 1); and (2) model 1 
plus neonatal morbidities (infant respiratory distress syndrome, 
intraventricular hemorrhage, and sepsis) (Model 2). These con-
founders were selected based on the literature or on differences in 
baseline characteristics between the 3 groups (Table 1).
For measures yielding multiple outcomes (MCT, Touwen’s ex-
amination of minor neurologic dysfunction, YASR, and YABCL), 
α was adjusted to 0.01 to reduce the risk for type 1 errors. For the 
other outcomes, p < 0.05 was considered significant.
For all analyses, the VP+/VLBW+ group was used as the refer-
ence group.
Results
Perinatal Characteristics
At the age of 19 years, 959 of the 1,338 subjects were 
alive, and 705 of them (73.5%) had been successfully fol-
lowed up. Of the deceased, 96% had died within the first 
year of life (Fig. 1). The characteristics of responders and 
nonresponders did not significantly differ, except for 
Table 1. Perinatal characteristics of the 3 groups and the nonresponders
VP+/VLBW+ 
(n = 354)
VP+/VLBW– 
(n = 144)
VP–/VLBW+ 
(n = 207)
Overall 
p value
Nonresponders 
(n = 254)
p value
Male 154 (43.5) 85 (59.0) 89 (43.0) 0.003a, b 169 (66.5) <0.001
Birth weight, g 1,161±211 1,721±196 1,275±175 <0.001a–c 1,327±256 0.387
Gestational age, weeks 29.3±1.5 30.7±1.0 34.0±1.6 <0.001a–c 31.2±2.7 0.352
PROM 82 (23.2) 37 (25.7) 8 (3.9) <0.001b, c 47 (18.5) 0.862
Born via Cesarian section 146 (41.2) 39 (27.1) 164 (79.2) <0.001a–c 107 (42.1) 0.044
Apgar score >7 after 5 min 279 (78.8) 125 (86.8) 185 (89.4) 0.003a, b 209 (82.3) 0.896
Duration of hospital stay, days 79±31 48±15 59±25 <0.001a–c 67±30 0.996
Days of ventilation, n 7.3±10.0 2.8±4.5 1.7±8.9 <0.001a, b 4.8±10.3 0.887
IRDS 181 (51.1) 66 (45.8) 29 (14.0) <0.001b, c 97 (38.2) 0.788
Sepsis 141 (40.1) 35 (24.3) 50 (24.2) <0.001a, b 95 (37.4) 0.129
IVH 91 (25.7) 22 (15.3) 13 (6.3) <0.001a–c 39 (15.4) 0.362
NEC 24 (6.8) 8 (5.6) 11 (5.3) 0.747 12 (4.7) 0.419
SGA 36 (10.2) 2 (1.4) 159 (76.8) <0.001a–c 75 (29.5) 0.631
Values represent mean ± SD or n (%). Continuous variables were compared with the one-way ANOVA test when comparing the 3 
groups, and the independent t test when comparing 2 groups. Dichotomous variables were compared with the χ2 test. VP, very preterm; 
VLBW, very low birth weight; PROM, premature rupture of the membranes; IRDS, infant respiratory distress syndrome; IVH, 
intraventricular hemorrhage; NEC, necrotizing enterocolitis; SGA, small-for-gestational-age.
a p < 0.05 for VP+/VLBW+ versus VP+/VLBW–.
b p < 0.05 for VP+/VLBW+ versus VP–/VLBW+.
c p < 0.05 for VP+VLBW– versus VP–/VLBW+.
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there being more males and slightly fewer Cesarian births 
among the latter (Table 1). The distribution of the sub-
jects across the 3 groups was also not significantly differ-
ent with regard to responders and nonresponders (p = 
0.93).
Perinatal characteristics significantly differed in the 3 
groups (Table 1). In general, infants in the VP–/VLBW+ 
group had fewer neonatal morbidities than the other 2 
groups but were more often SGA. The VP+/VLBW+ 
group had the highest prevalence of neonatal morbidity, 
along with a longer hospital stay and more days on ven-
tilation. The VP+/VLBW– group had the shortest hospi-
tal stay and the least SGA births.
Neurodevelopmental Outcomes
Cognitive Functioning
A trend towards a higher total IQ in the VP+/VLBW– 
group versus the VP+/VLBW+ group was observed (0.05 > 
p > 0.01) (Table 2). No associations or trends were present 
in Models 1 and 2.
The subscore mathematical capacity was significantly 
higher in the VP+/VLBW– group. This association be-
came nonsignificant (p > 0.01) in Models 1 and 2.
Neuromotor Function
Total neuromotor score was comparable in the 3 
groups (Table 2). However, a trend (0.05 > p > 0.01) to-
wards a higher passive muscle tone subscore in the VP+/
VLBW– group compared to the VP+/VLBW+ group was 
present, persisting in both models.
Hearing Loss
Hearing loss was significantly less for both the worst 
and best ear in the VP+/VLBW– group, in the crude and 
adjusted analyses (Table 2). No differences were found 
between the VP+/VLBW+ and VP–/VLBW+ groups.
Behavioral and Emotional Functioning
In the VP+/VLBW– group, the adolescents themselves 
and their parents reported lower scores on the Anxious/
depressed syndrome scale, as well as on the “Internalizing 
behavior” problem scale compared to the VP+/VLBW+ 
group (Table 3). The parents also reported fewer Atten-
tion problems. A trend (0.05 > p > 0.01) towards fewer 
self-reported Attention problems as well as “Total prob-
lems” behavior was present in the VP+/VLBW– group. 
Most of these associations and trends were still present in 
both models. Adolescents in the VP–/VLBW+ group 
showed a trend towards a higher score on the Withdrawn 
behavior syndrome scale, both in the crude and adjusted 
analysis.
Functional Outcomes
Educational Achievement
No differences were found in worst-case coding edu-
cation in the 3 groups (Table 2). However, a trend to-
wards higher educational achievement in the VP+/
VLBW– group than in the VP+/VLBW+ group appeared 
to be present. Repeated analyses for best-case coding 
found similar results (data not shown).
Occupation
No differences were found between the 3 groups (Ta-
ble 2). Most subjects did not experience a problem with 
regard to occupation.
Health Status
The VP–/VLBW+ group had higher odds of reporting 
a lower health status than the VP+/VLBW+ group did 
(Table 2). This association remained significant in both 
models. 
1,338 infants
included
379 deceased:
363 <1 year
16 ≥1 year
959 subjects
alive at age 19
254 non
responders
705 subjects
with follow-up
354 VP+/VLBW+ 144 VP+/VLBW– 207 VP–/VLBW+
Fig. 1. Flowchart of the follow-up response of POPS subjects at the 
age of 19 years.
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Perceived Health
No significant differences were found in the perceived 
health of the 3 groups (Table 2), although there was a 
nonsignificant tendency towards higher odds of report-
ing worse perceived health in the VP–/VLBW+ group 
(Table 2).
Discussion
In our study, we found that the long-term outcomes of 
VP+/VLBW– subjects were more favorable than those of 
VP+/VLBW+ subjects. On average, the subjects in the 
VP+/VLBW– group had a trend towards a higher IQ 
score, as well as less hearing loss and less self- and parent-
reported behavioral problems. Additionally, a trend to-
wards higher educational achievement was found in this 
group. Compared to the VP+/VLBW+ group, the VP–/
VLBW+ group reported worse self-perceived health. 
None of the observed differences were reflected in par-
ticipants’ occupational achievement.
Some associations became nonsignificant after correc-
tion for demographic and/or perinatal morbidity vari-
ables. Indeed, these factors have previously been identi-
fied as predictors for poor outcomes in preterm infants 
[21–24]. On the other hand, other associations remained 
significant after correction for these variables. However, 
it is unclear whether the loss of statistical significance for 
some associations was due to (appropriate) correction for 
confounding variables or (inappropriate) correction for 
intermediate variables in the causal pathway. Neverthe-
less, neurodevelopmental and functional outcomes still 
appeared significantly different in infants born VP+/
VLBW+, VP+/VLBW–, and VP–/VLBW+ after analyses 
were adjusted for demographic and neonatal morbidity.
Our findings confirm that the entities VP and VLBW 
are not interchangeable. Previous research has shown 
that these two entities are associated with different short-
term outcomes [10], with a higher proportion of neonatal 
morbidities in the VP+/VLBW+ and VP+/VLBW– 
groups, but more SGA births in the VP–/VLBW+ group. 
Moreover, we have recently shown that different growth 
patterns up until final height are also present, with the 
best growth in VP+/VLBW– infants, while subjects in the 
VP–/VLBW+ group remain the shortest and lightest [11]. 
In this study, we also found differences in neurodevelop-
mental and functional outcomes between the terms VP 
and VLBW, contributing to the evidence that these two 
entities are indeed not the same.
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The differences found in our study were statistically 
significant, but the effect sizes were modest, and the dif-
ferences in the three groups are also likely smaller than 
if the groups had been compared to a VP–/VLBW– 
control group. The clinical implications therefore re-
main to be determined. Our findings mostly have im-
plications for (clinical) research. For future studies on 
preterm infants, we recommend using the same inclu-
sion criteria, thereby enabling comparisons between 
cohorts. Previously, recommendations have been made 
to base epidemiologic studies on preterm infants on GA 
rather than on BW [25–28]. However, as far as we are 
aware, these studies only researched short-term (in-
hospital) outcomes. The results of our study on long-
term neurodevelopmental differences, as well as our 
previous study on long-term growth outcomes, have 
added to the available evidence, showing that the differ-
ences between VP and VLBW subjects remain present 
into adolescence [11]. Therefore, since prematurity is 
defined by GA and since pregnancy duration can be 
measured accurately with current technology [29, 30], 
we concur with the previous recommendations that GA 
should be used as an inclusion criterion instead of BW, 
at least in industrialized countries. Simultaneously, we 
also recommend adjusting for BW SD scores when an-
alyzing (long-term) outcomes, since BW is a strong de-
terminant of long-term neurodevelopmental outcomes 
[9, 31, 32]. 
The results of studies on VLBW infants cannot auto-
matically be applied to a VP population, and vice versa; 
this should be taken into account when interpreting the 
results of a study on VP or VLBW infants. Nevertheless, 
the effect sizes found in our study were small, and VP and 
VLBW populations often do overlap with regard to clini-
cal care. The substantial established body of literature, on 
both VP and VLBW subjects, therefore remains extreme-
ly valuable. However, especially as infants with increas-
ingly younger GA are now being treated, we recommend 
that future studies select preterm populations primarily 
based on GA. 
Our study has several strengths and limitations. Its 
major strengths are its large sample size, long-term fol-
low-up, the analytical approach that adjusted for mul-
tiple potential confounders, and the use of a broad range 
of neurodevelopmental and functional outcomes. It also 
has its limitations. Although we found several differenc-
es in neurodevelopmental and functional outcomes in 
the 3 groups, the mechanism behind these differences 
cannot be elucidated with the available data, since the 
etiology of these outcomes is most likely complex and 
multifactorial. Additionally, since 1983, improvements 
in neonatal care have been made, while infants with an 
increasingly younger GA are being treated, and intra-
uterine growth is better monitored. A VP and/or VLBW 
cohort is therefore likely to have a different composition 
nowadays, and the results of this study, as well as the 
etiology behind these results, can therefore not neces-
sarily be applied to the current generation of preterm 
infants. However, while mortality has decreased, mor-
bidity has increased [12], which could entail a higher 
risk for adverse neurodevelopmental and functional 
outcomes. Moreover, using either VP or VLBW as an 
inclusion criterion will most likely still lead to different 
outcomes. Additionally, we performed multiple statisti-
cal tests, and so it is possible that some of the associa-
tions were due to chance, even after adjusting the α to 
0.01 for measures that yielded multiple outcomes. Our 
results should therefore be interpreted with caution. 
Lastly, the gender distribution differed between re-
sponders and nonresponders. However, since none of 
the other characteristics, as well as the distribution of 
subjects across groups, were different, it is unlikely that 
our results were subject to attrition bias, although this 
cannot be ruled out.
In conclusion, subjects born VP+/VLBW+, VP+/
VLBW–, and VP–/VLBW+ had significantly different 
neurodevelopmental and functional outcomes, although 
effect sizes were small. Moreover, previous research has 
shown that the terms VP and VLBW also lead to differ-
ent short- and long-term outcomes [10, 11], indicating 
that these entities are not the same. We recommend, at 
least in industrialized countries, that inclusion for future 
studies in preterm populations be based on GA instead 
of BW.
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